

Technical Review Panel Member

Curriculum Vitae

Name: **Lasse S. Vestergaard**

Nationality: **Danish**

Additional languages: **English**

Expertise: **Malaria** (case management / diagnosis and treatment / antimalarial drug resistance / epidemiology and surveillance / information systems / laboratory services / drug procurement and supply chain systems / malaria control and elimination policies and strategies / malaria program management and implementation / monitoring and evaluation / staff training and capacity building / project evaluation / national malaria program reviews / operational research / health systems strengthening).

Qualifications

Qualification	Institution	Department	Year
Board Certified Specialist in Public Health Medicine	Ministry of Health, Denmark	National Board of Health	2018
PhD (malaria epidemiology)	University of Copenhagen, Denmark	Faculty of Medicine	2005
Medical Doctor (MD)	University of Copenhagen, Denmark	Faculty of Medicine	1999

Employment History

Employer	Position	Place	Year
National Institute of Infectious Diseases (SSI), Infection Epidemiology and Prevention, National Malaria Reference Laboratory	Senior Medical Officer, Team Leader	Copenhagen, Denmark	2017-present
Department of Clinical Microbiology, Copenhagen University Hospital	Medical Officer, Clinical Microbiology	Copenhagen, Denmark	2015-2016
WHO, Regional Office for the Western Pacific	Medical Officer for Malaria, other Vector-Borne and Parasitic Diseases	Manila, Philippines	2013-2015
WHO, Country Office for the Philippines	Medical Officer for Malaria, other Vector-Borne and Parasitic Diseases	Manila, Philippines	2012-2013
WHO, Country Office for Vanuatu	Medical Officer for Malaria, other Vector-Borne and Parasitic Diseases	Port Vila, Vanuatu	2008-2012
Department of Infectious Diseases, Copenhagen University Hospital	Resident, Clinical Infectious Diseases	Copenhagen, Denmark	2007-2008

National Institute of Infectious Diseases (SSI), Parasitology Laboratory, National Malaria Reference Laboratory	Medical Officer	Copenhagen, Denmark	2004-2007
Centre for Medical Parasitology (CMP), University of Copenhagen	Clinical Research Fellow	Copenhagen, Denmark Tanga, Tanzania	2001-2004

Relevant publications, reports, guidelines

Malaria publications in peer-reviewed journals (selected)

- Francis J, Barnes KI, Workman L, Kredo T, **Vestergaard LS**, Hoglund RM, Byakika-Kibwika P, Lamorde M, Walimbwa SI, Chijioke-Nwauche I, Sutherland CJ, Merry C, Scarsi KK, Nyagonde N, Lemnge MM, Khoo SH, Bygbjerg IC, Parikh S, Aweeka FT, Tarning J, Denti P. An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. *Antimicrob Agents Chemother*, 2020; 64:e02394-19. DOI: 1128/AAC.02394-19.
- Hartmeyer GN, Stensvold CR, Fabricius T, Marmolin ES, Hoegh S, Nielsen HV, Kemp M, **Vestergaard LS**. *Plasmodium cynomolgi* as cause of malaria in tourist to Southeast Asia, 2018. *Emerging Infectious Diseases*, 2019; 25: 1936-1939. DOI: 10.3201/eid2510.190448.
- Sondén K, Rolling T, Wångdahl A, Ydring E, Vygen-Bonnet S, Kobbe R, Douhan J, Hammar U, Herrador BG, Duijster J, Freedman J, Gysin N, Stark K, Stevens F, **Vestergaard LS**, Tegnell A, Färnert A. Exceptional increase of malaria in Europe due to imported *Plasmodium vivax* in Eritrean migrants during 2014-2015. *Euro Surveill*, 2019 Jan;24(5). DOI: 10.2807/1560-7917.ES.2019.24.5.1800139.
- Bruxvoort K, Leurent B, Chandler C, Ansah E, Baiden F, Bjorkman A, Burchett H, Clarke S, DiLiberto D, Elfving K, Goodman C, Hansen K, Kachur P, Lal S, Lalloo D, Leslie T, Magnussen P, Mangham-Jefferies L, Martensson A, Mayan I, Mbonye A, Msellem M, Onwujekwe O, Owusu-Agyei S, Rowland M, Shakely D, Staedke S, **Vestergaard LS**, Webster J, Whitty C, Wiseman V, Yeung S, Schellenberg D, Hopkins H. The impact of introducing malaria rapid diagnostic tests on fever case management: A synthesis of ten studies from the ACT Consortium. *Am J Trop Med Hyg*, 2017; 97:1170-1179. doi: 10.4269/ajtmh.16-0955.
- Hopkins H, Bruxvoort KJ, Cairns ME, Chandler CI, Leurent B, Ansah EK, Baiden F, Baltzell KA, Björkman A, Burchett HE, Clarke SE, DiLiberto DD, Elfving K, Goodman C, Hansen KS, Kachur SP, Lal S, Lalloo DG, Leslie T, Magnussen P, Jefferies LM, Mårtensson A, Mayan I, Mbonye AK, Msellem MI, Onwujekwe OE, Owusu-Agyei S, Reyburn H, Rowland MW, Shakely D, **Vestergaard LS**, Webster J, Wiseman VL, Yeung S, Schellenberg D, Staedke SG, Whitty CJ. Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings. *BMJ*. 2017 Mar 29;356:j1054. doi: 10.1136/bmj.j1054.
- Burchett HE, Leurent B, Baiden F, Baltzell K, Björkman A, Bruxvoort K, Clarke S, DiLiberto D, Elfving K, Goodman C, Hopkins H, Lal S, Liverani M, Magnussen P, Mårtensson A, Mbacham W, Mbonye A, Onwujekwe O, Roth Allen D, Shakely D, Staedke S, **Vestergaard LS**, Whitty CJ, Wiseman V, Chandler CI. Improving prescribing practices with rapid diagnostic tests (RDTs): synthesis of 10 studies to explore reasons for variation in malaria RDT uptake and adherence. *BMJ Open*. 2017 Mar 8;7(3):e012973. doi: 10.1136/bmjopen-2016-012973.
- Donald W, Pasay C, Guintran JO, Iata H, Anderson K, Nausien J, Gresty KJ, Waters NC, **Vestergaard LS**, Taleo G, Cheng Q. The utility of malaria rapid diagnostic tests as a tool in enhanced surveillance for malaria elimination in Vanuatu. *PLoS One*, 2016 Nov 30;11(11): e0167136. doi: 10.1371/journal.pone.0167136.

8. McEwen J, **Vestergaard LS**, Sanburg AL. Pacific Island Pharmacovigilance: The Need for a Different Approach. *Drug Safety*, 2016 Oct;39(10):891-4. doi: 10.1007/s40264-016-0439-4.
9. Leang R, Canavati SE, Khim N, **Vestergaard LS**, Borghini Fuhner I, Kim S, Denis MB, Heng P, Tol B, Huy R, Duparc S, Dondorp AM, Menard D, Ringwald P. Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in western Cambodia. *Antimicrobial Agents and Chemotherapy*, 2016 Feb 29. pii: AAC.00039-16. doi: 10.1128/AAC.00039-16.
10. Drabe CH, **Vestergaard LS**, Helleberg M, Nyagonde N, Rose MV, Francis F, Theilgaard OP, Asbjørn J, Amos B, Bygbjerg IC, Ruhwald M, Ravn P. Per Performance of Interferon-Gamma and IP-10 Release Assays for Diagnosing Latent Tuberculosis Infections in Patients with Concurrent Malaria in Tanzania. *Am J Trop Med Hyg*. 2016 Apr;94(4):728-35. doi: 10.4269/ajtmh.15-0633.
11. Turner L, Lavtsen T, Mmbando BP, Wang CW, Magistrado PA, **Vestergaard LS**, Ishengoma DS, Minja DT, Lusingu JP, Theander TG. IgG antibodies to endothelial protein C receptor-binding cysteine-rich interdomain region domains of Plasmodium falciparum erythrocyte membrane protein 1 are acquired early in life in individuals exposed to malaria. *Infect Immun*. 2015 Aug;83(8):3096-103. doi: 10.1128/IAI.00271-15.
12. Mangesho PE, Reynolds J, Lemnge M, **Vestergaard LS**, Chandler CI. "Every drug goes to treat its own disease..." - a qualitative study of perceptions and experiences of taking anti-retrovirals concomitantly with anti-malarials among those affected by HIV and malaria in Tanzania. *Malaria Journal*, 2014;13:491. doi: 10.1186/1475-2875-13-491.
13. Reynolds J, DiLiberto D, Mangham-Jefferies L, Ansah EK, Lal S, Mbakilwa H, Bruxvoort K, Webster J, **Vestergaard LS**, Yeung S, Leslie T, Hutchinson E, Reyburn H, Lalloo DG, Schellenberg D, Cundill B, Staedke SG, Wiseman V, Goodman C, Chandler CI. The practice of 'doing' evaluation: lessons learned from nine complex intervention trials in action. *Implementation Science*. 2014 Jun 17;9: 75. doi: 10.1186/1748-5908-9-75.
14. Allen EN, Mushi AK, Massawe IS, **Vestergaard LS**, Lemnge M, Staedke SG, Mehta U, Barnes KI, Chandler CI. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. *BMC Med Res Methodol*, 2013;14:13:140. doi: 10.1186/1471-2288-13-140.
15. Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, Bansil P, Carter N, Cheng Q, Culpepper J, Eziefule C, Fukuda M, Green J, Hwang J, Lacerda M, McGray S, Menard D, Nosten F, Nuchprayoon I, Oo NN, Bualombai P, Pumpradit W, Qian K, Recht J, Roca A, Satimai W, Sovannaroeth S, **Vestergaard LS**, Von Seidlein L. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. *Malar Journal*, 2013 Nov 4;12:391. doi: 10.1186/1475-2875-12-391.
16. Smith Gueye C, Sanders KC, Galappaththy GN, Rundi C, Tobgay T, Sovannaroeth S, Gao Q, Surya A, Thakur GD, Baquilod M, Lee WJ, Bobogare A, Deniyage SL, Satimai W, Taleo G, Hung NM, Cotter C, Hsiang MS, **Vestergaard LS**, Gosling RD. Active case detection for malaria elimination: a survey among Asia Pacific countries. *Malaria Journal*, 2013 Oct 9;12:358. doi: 10.1186/1475-2875-12-358.
17. Kelly GC, Hale E, Donald W, Batarii W, Bugoro H, Nausien J, Smale J, Palmer K, Bobogare A, Taleo G, Vallely A, Tanner M, **Vestergaard LS**, Clements AC. A high-resolution geospatial surveillance-response system for malaria elimination in Solomon Islands and Vanuatu. *Malaria Journal*, 2013; 12:108. doi: 10.1186/1475-2875-12-108.
18. Liu JX, Newby G, Brackery A, Smith Gueye C, Candari CJ, Escubil LR, **Vestergaard LS**, Baquilod M. Determinants of malaria program expenditures during elimination: case study evidence from select provinces in the Philippines. *PLoS One*, 2013 Sep 27;8(9):e73352. doi: 10.1371/journal.pone.0073352.
19. Reynolds J, Mangesho P, Lemnge MM, **Vestergaard LS**, Chandler CI. '... in the project they really care for us': meaning and experiences of participating in a clinical study of first-line treatment for malaria and HIV in Tanzanian adults. *Global Public Health*. 2013 Jul;8(6):670-84. doi: 10.1080/17441692.2013.810297.

20. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, Baird K, Moyes C, Howes R, Ménard D, Bancone G, Winasti-Satyahraha A, **Vestergaard LS**, Green J, Domingo G, Yeung S, Price R. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. *Malaria Journal*, 2013 Mar 27;12:112. doi: 10.1186/1475-2875-12-112.
21. Thomsen TT, Ishengoma DS, Mmbando BP, Lusingu JP, **Vestergaard LS**, Theander TG, Lemnge MM, Bygbjerg IC, Alifrangis M. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. *Am J Trop Med Hyg*. 2011 Dec;85(6):979-83. doi: 10.4269/ajtmh.2011.11-0071.
22. Kelly GC, Seng CM, Donald W, Taleo G, Nausien J, Batarii W, Iata H, Tanner M, **Vestergaard LS**, Clements AC. A spatial decision support system for guiding focal indoor residual interventions in a malaria elimination zone. *Geospatial Health*, 2011;6(1):21-31. doi: 10.4081/gh.2011.154.
23. Ishengoma DS, Lwitiho S, Madebe RA, Nyagonde N, Persson O, **Vestergaard LS**, Bygbjerg IC, Lemnge MM, Alifrangis M. Using rapid diagnostic tests as source of malaria parasite DNA for molecular analyses in the era of declining malaria prevalence. *Malaria Journal*, 2011 Jan 12;10:6. doi: 10.1186/1475-2875-10-6.
24. Victor ME, Bengtsson A, Andersen G, Bengtsson D, Lusingu JP, **Vestergaard LS**, Arnot DE, Theander TG, Joergensen L, Jensen AT. Insect cells are superior to Escherichia coli in producing malaria proteins inducing IgG targeting PfEMP1 on infected erythrocytes. *Malaria Journal*. 2010 Nov 15;9:325. doi: 10.1186/1475-2875-9-325.
25. Olesen CH, Brahimi K, Vandahl B, Lousada-Dietrich S, Jogdand PS, **Vestergaard LS**, Dodoo D, Højrup P, Christiansen M, Larsen SO, Singh S, Theisen M. Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections. *Malaria Journal*, 2010 Oct 26;9:296. doi: 10.1186/1475-2875-9-296.
26. Behrens RH, Carroll B, Hellgren U, Visser LG, Siikamäki H, **Vestergaard LS**, Calleri G, Jänisch T, Myrvang B, Gascon J, Hatz C. The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator? *Malaria Journal*, 2010 Oct 4;9:266. doi: 10.1186/1475-2875-9-266.
27. Khalil IF, Abildrup U, Alifrangis LH, Maiga D, Alifrangis M, Hoegberg L, **Vestergaard LS**, Persson OP, Nyagonde N, Lemnge MM, Theander TG, Bygbjerg IC. Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection. *J Pharm Biomed Anal*. 2011 Jan 5;54(1):168-72. doi: 10.1016/j.jpba.2010.08.009.
28. Mmbando BP, **Vestergaard LS**, Kitua AY, Lemnge MM, Theander TG, Lusingu JP. A progressive declining in the burden of malaria in north-eastern Tanzania. *Malaria Journal*, 2010 Jul 23;9:216. doi: 10.1186/1475-2875-9-216.
29. Haissman JM, **Vestergaard LS**, Sembuche S, Erikstrup C, Mmbando B, Mtullu S, Lemnge MM, Gerstoft J, Ullum H. Plasma cytokine levels in Tanzanian HIV-1-infected adults and the effect of antiretroviral treatment. *J Acquir Immune Defic Syndr*. 2009 Dec 1;52(4):493-7. doi: 10.1097/QAI.0b013e3181b627dc.
30. Mmbando BP, Lusingu JP, **Vestergaard LS**, Lemnge MM, Theander TG, Scheike TH. Parasite threshold associated with clinical malaria in areas of different transmission intensities in north eastern Tanzania. *BMC Med Res Methodol*. 2009 Nov 12;9:75. doi: 10.1186/1471-2288-9-75.
31. Cham GK, Turner L, Lusingu J, **Vestergaard LS**, Mmbando BP, Kurtis JD, Jensen AT, Salanti A, Lavstsen T, Theander TG. Sequential, ordered acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 domains. *J Immunol*. 2009 Sep 1;183(5):3356-63. doi: 10.4049/jimmunol.0901331.
32. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, **Vestergaard LS**, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. *Am J Trop Med Hyg*. 2009 Apr;80(4):523-7.

33. Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, Theander TG, **Vestergaard LS**. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. *Am J Trop Med Hyg*. 2008 May;78(5):714-20.
34. **Vestergaard LS**, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, Akanmori BD, Alifrangis M, Bygbjerg IC, Lemnge MM, Staalsoe T, Hviid L, Theander TG. Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. *Infection & Immunity*. 2008 Jun;76(6):2706-14. doi: 10.1128/IAI.01401-06.
35. **Vestergaard LS**, Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. *American Journal of Tropical Medicine and Hygiene*, 2007 Dec;77(6 Suppl):153-9.
36. Enevold A, Nkya WM, Theisen M, **Vestergaard LS**, Jensen AT, Staalsoe T, Theander TG, Bygbjerg IC, Alifrangis M. Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. *Malaria Journal*, 2007 Nov 16;6:153. doi: 10.1186/1475-2875-6-153.
37. Enevold A, Alifrangis M, Sanchez JJ, Carneiro I, Roper C, Børsting C, Lusingu J, **Vestergaard LS**, Lemnge MM, Morling N, Riley E, Drakeley CJ. Associations between alpha+-thalassemia and Plasmodium falciparum malarial infection in northeastern Tanzania. *J Infect Dis*. 2007 Aug 1;196(3):451-9. doi: 10.1086/519390.
38. Magistrado PA, Lusingu J, Vestergaard LS, Lemnge M, Lavstsen T, Turner L, Hviid L, Jensen AT, Theander TG. Immunoglobulin G antibody reactivity to a group A Plasmodium falciparum erythrocyte membrane protein 1 and protection from P. falciparum malaria. *Infect Immun*. 2007 May;75(5):2415-20. doi: 10.1128/IAI.00951-06.
39. Gjørup IE, **Vestergaard LS**, Møller K, Rønn AM, Bygbjerg IC. Laboratory indicators of the diagnosis and course of imported malaria. *Scand J Infect Dis*. 2007;39(8):707-13. doi: 10.1080/00365540701225710.
40. Joergensen L, **Vestergaard LS**, Turner L, Magistrado P, Lusingu JP, Lemnge M, Theander TG, Jensen AT. 3D7-Derived Plasmodium falciparum erythrocyte membrane protein 1 is a frequent target of naturally acquired antibodies recognizing protein domains in a particular pattern independent of malaria transmission intensity. *Journal of Immunology*, 2007 Jan 1;178(1):428-35. doi: 10.4049/jimmunol.178.1.428.
41. Joergensen L, Turner L, Magistrado P, Dahlbäck MA, **Vestergaard LS**, Lusingu JP, Lemnge M, Salanti A, Theander TG, Jensen AT. Limited cross-reactivity among domains of the Plasmodium falciparum clone 3D7 erythrocyte membrane protein 1 family. *Infect Immun*. 2006 Dec;74(12):6778-84. doi: 10.1128/IAI.01187-06.
42. Alifrangis M, Dalgaard MB, Lusingu JP, **Vestergaard LS**, Staalsoe T, Jensen AT, Enevold A, Rønn AM, Khalil IF, Warhurst DC, Lemnge MM, Theander TG, Bygbjerg IC. Occurrence of the Southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. *J Infect Dis*. 2006 Jun 15;193(12):1738-41. doi: 10.1086/504269.
43. Lusingu JP, Jensen AT, **Vestergaard LS**, Minja DT, Dalgaard MB, Gesase S, Mmbando BP, Kitua AY, Lemnge MM, Cavanagh D, Hviid L, Theander TG. Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semiconserved Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes. *Infect Immun*. 2006 May;74(5):2867-75. doi: 10.1128/IAI.74.5.2867-2875.2006.
44. Enevold A, **Vestergaard LS**, Lusingu J, Drakeley CJ, Lemnge MM, Theander TG, Bygbjerg IC, Alifrangis M. Rapid screening for glucose-6-phosphate dehydrogenase deficiency and haemoglobin polymorphisms in Africa by a simple high-throughput SSOP-ELISA method. *Malaria Journal*, 2005 Dec 15;4:61. doi: 10.1186/1475-2875-4-61.
45. Lusingu JP, **Vestergaard LS**, Alifrangis M, Mmbando BP, Theisen M, Kitua AY, Lemnge MM, Theander TG. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. *Malaria Journal*, 2005 Sep 29;4:48. doi: 10.1186/1475-2875-4-48.

46. Lusingu JP, **Vestergaard LS**, Mmbando BP, Drakeley CJ, Jones C, Akida J, Savaeli ZX, Kitua AY, Lemnge MM, Theander TG. Malaria morbidity and immunity among residents of villages with different *Plasmodium falciparum* transmission intensity in North-Eastern Tanzania. *Malaria Journal*, 2004 Jul 28;3:26. doi: 10.1186/1475-2875-3-26.
47. Nielsen MA, **Vestergaard LS**, Lusingu J, Kurtzhals JA, Giha HA, Grevstad B, Goka BQ, Lemnge MM, Jensen JB, Akanmori BD, Theander TG, Staalsoe T, Hviid L. Geographical and temporal conservation of antibody recognition of *Plasmodium falciparum* variant surface antigens. *Infection and Immunity*, 2004 Jun;72(6):3531-5. doi: 10.1128/IAI.72.6.3531-3535.2004.
48. Jensen AT, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiacchiuini A, Salanti A, **Vestergaard LS**, Lusingu JP, Hermsen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T, Theander TG. *Plasmodium falciparum* associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes. *J Exp Med*. 2004 May 3;199(9):1179-90. doi: 10.1084/jem.20040274.
49. Staalsoe T, Nielsen MA, **Vestergaard LS**, Jensen AT, Theander TG, Hviid L. In vitro selection of *Plasmodium falciparum* 3D7 for expression of variant surface antigens associated with severe malaria in African children. *Parasite Immunol*. 2003 Aug-Sep;25(8-9):421-7. doi: 10.1111/j.1365-3024.2003.00652.x.
50. David KP, Alifrangis M, Salanti A, **Vestergaard LS**, Rønn A, Bygbjerg IB. Atovaquone/proguanil resistance in Africa: a case report. *Scand J Infect Dis*. 2003;35(11-12):897-8.

Selected other publications (technical documents, reports, WHO guidelines and strategies, etc.)

1. Vanuatu Malaria Programme Review Report. UNDP, Suva Fiji, January 2019.
2. Myanmar Malaria Programme Review Report. WHO. Yangon, Myanmar, April 2019.
3. Strategy for the Elimination of Malaria in the Greater Mekong Subregion 2015-2030. World Health Organization, Geneva, Switzerland, 2015.
4. Global Technical Strategy for Malaria 2016-2030. World Health Organization, Geneva, Switzerland, 2015.
5. World Malaria Report 2010, 2011, 2012, 2013 and 2014. WHO, Geneva.
6. Philippines Malaria Elimination Case Study Report. WHO, Global Health Group and Department of Health, Government of Philippines, Manila, Philippines, 2014.
7. Philippines National Malaria Program Review Report. WHO Philippines, Manila, Philippines, 2013.
8. Regional Strategy for Malaria Control and Elimination in the Western Pacific Region 2010-2015. WHO-WPRO, Manila, Philippines, 2010.
9. Progress in malaria control and moving towards elimination in Solomon Islands and Vanuatu. World Health Organization, Western Pacific Regional Office, Manila, Philippines, 2012.
10. WHO Guidelines for the Treatment of Malaria. Global Malaria Programme, World Health Organization, Geneva, 2005 (member of the WHO Malaria Treatment Guideline Development Group).
11. Methods for the Surveillance of Antimalarial Drug Efficacy. WHO, Geneva, Switzerland, 2009.
12. Template protocol for the testing of therapeutic efficacy of antimalarial drugs for the treatment of uncomplicated *Plasmodium falciparum* malaria. World Health Organization, Geneva, 2006.
13. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Report from informal consultation organized by Medicines for Malaria Venture (MMV) and the World Health Organization, Amsterdam 29-31 May 2007.
14. Review of antimalarial treatment choices for the Global Fund approved grants to countries for rounds 1-3. For the Global Fund to Fight Aids, Tuberculosis and Malaria, Geneva, June 2004.

Additional Information

Independent consultant in malaria control and elimination, e.g. involved in national malaria program reviews, development of national malaria strategic plans, national malaria treatment guidelines, etc.

Lecturer in global health, School of Global Health, University of Copenhagen, Copenhagen, Denmark.